ACAM 2000

Drug Profile

ACAM 2000

Alternative Names: ACAM 1000; ACAM2000; Smallpox (vaccinia) live vaccine - Sanofi Pasteur Biologics; Smallpox vaccine - Sanofi Pasteur Biologics

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur Biologics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Smallpox

Most Recent Events

  • 25 Sep 2008 Acambis has been acquired by sanofi pasteur
  • 31 Aug 2007 Registered for Smallpox (Available for use in military personnel and stockpiled for emergency use) in USA (Transdermal)
  • 17 May 2007 The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) votes unanimously in favour of ACAM 2000
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top